OBJECTIVE: To compare the clinical effectiveness of single-dose azithromycin treatment with 7 days of amoxycillin treatment among Aboriginal children with acute otitis media (AOM) in rural and remote communities in the Northern Territory. DESIGN, SETTING AND PARTICIPANTS: Aboriginal children aged 6 months to 6 years living in 16 rural and remote communities were screened for AOM. Those diagnosed with AOM were randomly allocated to receive either azithromycin (30 mg/kg as a single dose) or amoxycillin (50mg/kg/day in two divided doses for a minimum of 7 days). We used a double-dummy method to ensure blinding. Our study was conducted from 24 March 2003 to 20 July 2005. MAIN OUTCOME MEASURES: Failure to cure AOM by the end of therapy; nasal carriage of Streptococcus pneumoniae and non-capsular Haemophilus influenzae (NCHi). RESULTS: We followed 306 of 320 children (96%) allocated to the treatment groups. Single-dose azithromycin did not reduce (or increase) the risk of clinical failure (50% failure rate [82/165]) compared with amoxycillin (54% failure rate [83/155]) (risk difference [RD], - 4% [95% CI, - 15% to 7%]; P = 0.504). Compared with amoxycillin, azithromycin significantly reduced the proportion of children with nasal carriage of S. pneumoniae (27% v 63%; RD, - 36% [95% CI, - 47% to - 26%]; P < 0.001) and NCHi (55% v 85%; RD, - 30% [95% CI, - 40% to - 21%]; P < 0.001). Nasal carriage of S. pneumoniae with intermediate or full resistance to penicillin was lower (but not significantly so) in the azithromycin group (10% v 16%), but this group had significantly increased carriage of azithromycin-resistant S. pneumoniae (10% v 3%; RD, 7% [95% CI, 0.1% to 12%]; P = 0.001). Carriage of beta-lactamase-producing NCHi was about 5% in both groups. CONCLUSION: Although azithromycin reduced nasal carriage of S. pneumoniae and NCHi, clinical failure was high in both treatment groups. The possibility of weekly azithromycin treatment in children with persistent AOM should be evaluated. TRIAL REGISTRATION: Australian Clinical Trials Registry ACTRN 12609000691246.
RCT Entities:
OBJECTIVE: To compare the clinical effectiveness of single-dose azithromycin treatment with 7 days of amoxycillin treatment among Aboriginal children with acute otitis media (AOM) in rural and remote communities in the Northern Territory. DESIGN, SETTING AND PARTICIPANTS: Aboriginal children aged 6 months to 6 years living in 16 rural and remote communities were screened for AOM. Those diagnosed with AOM were randomly allocated to receive either azithromycin (30 mg/kg as a single dose) or amoxycillin (50mg/kg/day in two divided doses for a minimum of 7 days). We used a double-dummy method to ensure blinding. Our study was conducted from 24 March 2003 to 20 July 2005. MAIN OUTCOME MEASURES: Failure to cure AOM by the end of therapy; nasal carriage of Streptococcus pneumoniae and non-capsular Haemophilus influenzae (NCHi). RESULTS: We followed 306 of 320 children (96%) allocated to the treatment groups. Single-dose azithromycin did not reduce (or increase) the risk of clinical failure (50% failure rate [82/165]) compared with amoxycillin (54% failure rate [83/155]) (risk difference [RD], - 4% [95% CI, - 15% to 7%]; P = 0.504). Compared with amoxycillin, azithromycin significantly reduced the proportion of children with nasal carriage of S. pneumoniae (27% v 63%; RD, - 36% [95% CI, - 47% to - 26%]; P < 0.001) and NCHi (55% v 85%; RD, - 30% [95% CI, - 40% to - 21%]; P < 0.001). Nasal carriage of S. pneumoniae with intermediate or full resistance to penicillin was lower (but not significantly so) in the azithromycin group (10% v 16%), but this group had significantly increased carriage of azithromycin-resistant S. pneumoniae (10% v 3%; RD, 7% [95% CI, 0.1% to 12%]; P = 0.001). Carriage of beta-lactamase-producing NCHi was about 5% in both groups. CONCLUSION: Although azithromycin reduced nasal carriage of S. pneumoniae and NCHi, clinical failure was high in both treatment groups. The possibility of weekly azithromycin treatment in children with persistent AOM should be evaluated. TRIAL REGISTRATION: Australian Clinical Trials Registry ACTRN 12609000691246.
Authors: Michael J Binks; Allen C Cheng; Heidi Smith-Vaughan; Theo Sloots; Michael Nissen; David Whiley; Joseph McDonnell; Amanda J Leach Journal: BMC Infect Dis Date: 2011-06-07 Impact factor: 3.090
Authors: Kristin E D Weimer; Richard A Juneau; Kyle A Murrah; Bing Pang; Chelsie E Armbruster; Stephen H Richardson; W Edward Swords Journal: J Infect Dis Date: 2011-01-10 Impact factor: 5.226
Authors: Anne B Chang; Lucy C Morgan; Emma L Duncan; Mark D Chatfield; André Schultz; Paul J Leo; Gabrielle B McCallum; Aideen M McInerney-Leo; Steven M McPhail; Yuejen Zhao; Catherine Kruljac; Heidi C Smith-Vaughan; Peter S Morris; Julie M Marchant; Stephanie T Yerkovich; Anne L Cook; Danielle Wurzel; Lesley Versteegh; Hannah O'Farrell; Margaret S McElrea; Sabine Fletcher; Heather D'Antoine; Enna Stroil-Salama; Phil J Robinson; Keith Grimwood Journal: BMJ Open Respir Res Date: 2022-05
Authors: Heidi C Smith-Vaughan; Anne B Chang; Derek S Sarovich; Robyn L Marsh; Keith Grimwood; Amanda J Leach; Peter S Morris; Erin P Price Journal: Clin Vaccine Immunol Date: 2013-11-27
Authors: K M Hare; K Grimwood; A B Chang; M D Chatfield; P C Valery; A J Leach; H C Smith-Vaughan; P S Morris; C A Byrnes; P J Torzillo; A C Cheng Journal: Eur J Clin Microbiol Infect Dis Date: 2015-09-12 Impact factor: 3.267
Authors: Robyn L Marsh; Michael J Binks; Jemima Beissbarth; Peter Christensen; Peter S Morris; Amanda J Leach; Heidi C Smith-Vaughan Journal: BMC Ear Nose Throat Disord Date: 2012-10-03
Authors: Anne B Chang; Keith Grimwood; Andrew C Wilson; Peter P van Asperen; Catherine A Byrnes; Kerry-Ann F O'Grady; Theo P Sloots; Colin F Robertson; Paul J Torzillo; Gabrielle B McCallum; Ian B Masters; Helen M Buntain; Ian M Mackay; Jacobus Ungerer; Joanne Tuppin; Peter S Morris Journal: Trials Date: 2013-02-20 Impact factor: 2.279
Authors: Kim M Hare; Rosalyn J Singleton; Keith Grimwood; Patricia C Valery; Allen C Cheng; Peter S Morris; Amanda J Leach; Heidi C Smith-Vaughan; Mark Chatfield; Greg Redding; Alisa L Reasonover; Gabrielle B McCallum; Lori Chikoyak; Malcolm I McDonald; Ngiare Brown; Paul J Torzillo; Anne B Chang Journal: PLoS One Date: 2013-08-05 Impact factor: 3.240
Authors: Heidi C Smith-Vaughan; Michael J Binks; Robyn L Marsh; Mirjam Kaestli; Linda Ward; Kim M Hare; Susan J Pizzutto; Ruth B Thornton; Peter S Morris; Amanda J Leach Journal: BMC Ear Nose Throat Disord Date: 2013-10-08